ASPN Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Aspen Aerogels Inc (ASPN) is not a good buy for a beginner investor with a long-term focus and $50,000-$100,000 available for investment. The company is facing significant financial challenges, weak technical indicators, insider selling, and a lack of positive catalysts. Analysts have lowered price targets, and the options data suggests bearish sentiment. Given the investor's profile, this stock does not align with their goals.
The technical indicators for ASPN are bearish. The MACD is below 0 and negatively contracting, RSI is neutral at 48.066, and the moving averages indicate a bearish trend (SMA_200 > SMA_20 > SMA_5). Key support and resistance levels suggest the stock is closer to support at 3.106, with resistance at 3.656. Overall, the trend is weak and lacks upward momentum.
No significant positive catalysts identified. Analysts note potential long-term value, but near-term challenges dominate.
Financial performance is severely deteriorating, with revenue down 66.42% YoY and net income dropping 741.73% YoY in Q4
Insiders are selling heavily, with a 288.04% increase in selling activity over the last month.
Analysts have lowered price targets significantly, citing weak GM EV outlook and macroeconomic challenges.
No recent news or events to drive positive sentiment.
Aspen Aerogels reported a disastrous Q4 2025, with revenue dropping to $41.34M (-66.42% YoY), net income plunging to -$72.91M (-741.73% YoY), and EPS falling to -0.88 (-728.57% YoY). Gross margin also dropped to -55.47%, reflecting significant operational inefficiencies.
Analyst sentiment is mixed but leaning negative. Barclays downgraded the price target to $3 and maintains an Underweight rating. Roth Capital, B. Riley, and TD Cowen lowered price targets but maintain Buy ratings, citing long-term potential despite near-term challenges. Overall, analysts are cautious with reduced expectations.
